RETIFANLIMAB VS AVELUMAB IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA: A COST-UTILITY ANALYSIS IN ITALY

被引：0
|
作者：
Ghetti, G. [1 ]
Porta, C. [1 ]
Povero, M. [1 ]
Trimarchi, C. [2 ]
机构：
[1] AdRes HE, Turin, Italy
[2] Incyte Biosci Italy, Milan, MI, Italy
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE65
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [41] Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program
    Grignani, Giovanni
    Sileni, Vanna Chiarion
    Pinto, Carmine
    Depenni, Roberta
    Fazio, Nicola
    Galli, Luca
    Giuffrida, Dario
    Carnaghi, Carlo
    Ciliberto, Domenico
    Corsi, Domenico C.
    Queirolo, Paola
    Benincasa, Elena
    Venturini, Filippo
    Fazzi, Gennaro
    Costa, Nuno
    Ascierto, Paolo Antonio
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [42] Integrative molecular analysis of metastatic Merkel cell carcinoma to identify predictive biomarkers of response to avelumab.
    Georges, Sara
    Shah, Parantu K.
    Shapiro, Irina
    Hicking, Christine
    Lu, Lei
    Hennessy, Meliessa
    D'Angelo, Sandra P.
    Cai, Ti
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Cost-utility analysis of abatacept in rheumatoid arthritis in Italy
    de Portu, Simona
    Mantovani, Lorenzo Giovanni
    Olivieri, Ignazio
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2008, 9 (01) : 19 - 26
  • [44] Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
    Rognoni, Carla
    Falivena, Camilla
    Costa, Francesco
    Armeni, Patrizio
    PHARMACOECONOMICS, 2023, 41 (2) : 209 - 225
  • [45] Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
    Carla Rognoni
    Camilla Falivena
    Francesco Costa
    Patrizio Armeni
    PharmacoEconomics, 2023, 41 : 209 - 225
  • [46] A PHASE 2 STUDY OF RETIFANLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC MERKEL CELL CARCINOMA (MCC) (POD1UM-201)
    Grignani, Giovanni
    Rutkowski, Piotr
    Lebbe, Celeste
    Prinzi, Natalie
    Grob, Jean-jaques
    Tanda, Enrica Teresa
    Guida, Michele
    Burgess, Melissa
    Pulini, Jennifer
    Shankar, Sadhna
    Tian, Chuan
    Bhatia, Shailender
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A574 - A575
  • [47] Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma
    Kaufman, Howard L.
    Hunger, Matthias
    Hennessy, Meliessa
    Schlichting, Michael
    Bharmal, Murtuza
    FUTURE ONCOLOGY, 2018, 14 (03) : 255 - 266
  • [48] MINIMAL IMPACT ON PATIENTS' HEALTH UTILITIES ASSOCIATED WITH ADVERSE EVENTS IN METASTATIC MERKEL CELL CARCINOMA PATIENTS ON TREATMENT WITH AVELUMAB
    Kaufman, H.
    Hunger, M.
    Hennessy, M.
    Schlichting, M.
    Bharmal, M.
    VALUE IN HEALTH, 2017, 20 (09) : A448 - A448
  • [49] Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe
    Fife, Kate
    Tetu, Pauline
    Prabhakaran, Jessica
    Lebbe, Celeste
    Grignani, Giovanni
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [50] Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
    Sandra P. D’Angelo
    Matthias Hunger
    Andrew S. Brohl
    Paul Nghiem
    Shailender Bhatia
    Omid Hamid
    Janice M. Mehnert
    Patrick Terheyden
    Kent C. Shih
    Isaac Brownell
    Céleste Lebbé
    Karl D. Lewis
    Gerald P. Linette
    Michele Milella
    Michael Schlichting
    Meliessa H. Hennessy
    Murtuza Bharmal
    Cancer Immunology, Immunotherapy, 2019, 68 : 609 - 618
12345